Final KEYNOTE-048 Results With Frontline Pembrolizumab in Recurrent/Metastatic HNSCC

Jun 03, 2019

Danny Rischin, MD, director, Division of Cancer Medicine, head, Department of Medical Oncology, Peter MacCallum Cancer Centre, discusses results from the protocol-specified final analysis of the phase III KEYNOTE-048 trial of pembrolizumab (Keytruda) as frontline therapy for recurrent/metastatic head and neck squamous cell carcinoma.

Related Content

Clinically Meaningful Improvement in TRK Fusion Cancer Detected with Larotrectinib

Clinically Meaningful Improvement in TRK Fusion Cancer Detected with Larotrectinib

October 03, 2019 09:00pm

By Wayne Kuznar

Larotrectinib Maintains Safety and High Efficacy in TRK Fusion-Positive Cancer

Larotrectinib Maintains Safety and High Efficacy in TRK Fusion-Positive Cancer

September 29, 2019 10:49pm

Expert Suggests Novel Approaches To Improve CAR Therapies in ALL

Expert Suggests Novel Approaches To Improve CAR Therapies in ALL

September 13, 2019 02:23am

By Jason Harris

Clinical Trials in the Community Play Critical Role in Cancer Cure

Clinical Trials in the Community Play Critical Role in Cancer Cure

October 31, 2018 10:54pm

By James L. Wade III, MD, FACP, FASCO